Kornimate/medical-research-clean huggingface dataset:
comparing of cefazolin plus azithromycin versus cefazolin in prevention of febrile morbidity after emergency cesarean delivery

Conditions: Febrile Morbidity After Emergency Cesarean Section

Summary: cesarean section is the common surgery in world wide. but the complication like febrile morbidity such as surgical site infection, fever, urinary tract infection and endometritis can be occurred even giving the standard antibiotics. therefore if wider bacterial spectrum coverage antibiotic like azithromycin is added to the standard antimicrobial prophylaxis(1st generation cephalosporin), the incidence of febrile morbidity could be reduced. we will compare the regimen of cefazolin plus azithromycin and standard regimen of cefazolin alone in prevention of febrile morbidity after emergency cesarean section.

this study was designed to evaluate the effect of azithromycin on the incidence of febrile morbidity after the emergency cesarean section. the standard antimicrobial prophylaxis which is recommended by the acog is the 1st generation cephalosporin intravenously only but some of the bacteria that can cause the febrile morbidity after cesarean section wouldn't be killed by the 1st generation cephalosporin. the antibiotic that can cover them is macrolide group antibiotic such as azithromycin. therefore this study will compare the regimen of standard antimicrobial prophylaxis and the regimen of standard antimicrobial prophylaxis with azithromycin intravenously in preventing the febrile morbidity after emergency cesarean section. control group will receive the 1st generation cephalosporin intravenously and the intervention group will receive the 1st generation cephalosporin with azithromycin 500mg intravenously. primary outcome is febrile morbidity which assessed at postoperative day 3. the definition of the febrile morbidity in this study is including surgical site infection, endometritis, urinary tract infection and fever alone. secondary outcomes are febrile morbidity at postoperative day 7 and day30, neonatal outcome and adverse effect from azithromycin use.

Eligibility criteria:
inclusion criteria: 1. singleton pregnancy with a gestation of 24 weeks or more 2. undergoing non-elective cesarean delivery during labor or rupture of membrane more than 4 hr 3. no allergy to macrolide such as azithromycin and clindamycin 4. provide informed consent 5. partner of participant allows the patient to participate the research exclusion criteria: 1. use of azithromycin within 7 days before enrollment 2. chorioamnionitis or other infection requiring postpartum antibiotic therapy (except for antibiotics for group b streptococcus) 3. liver disease (cirrhosis or ast more than 3 times the upper normal limit) 4. serum creatinine level of more than 2.0 mg/dl or need dialysis 5. diarrhea at the time of enrollment 6. maternal heart disease 7. use of medication known to prolonged the qt interval
an open label study of severe sepsis in adults

Conditions: Severe Sepsis

Summary: this trial is to obtain safety data in adult patients with severe sepsis and two sepsis-induced organ infections who receive an infusion of drotrecogin alfa (activated).

to collect safety data while providing drotrecogin alfa (activated) for the treatment of patients with severe sepsis with multiple organ dysfunctions. patient access to drotrecogin alfa (activated) will be provided under this protocol prior to and during its review by the authorities of belgium and luxemburg for commercial release.

Eligibility criteria:
inclusion criteria: * patients greater than or equal 18 years of age may be included in this study only if they meet all of the following criteria: 1. must be 18 years. 2. suspected or proven infection 3. have or have had two or more sepsis-induced organ failures sepsis exclusion criteria: * patients will be excluded from entry in this study for any of the following reasons: 1. documented first organ dysfunction greater than 48-hours prior to start of study drug. 2. patients greater than 135 kg in weight. 3. patients with a platelet count less than 30,000/mm3 4. active internal bleeding or at increased risk for bleeding
low dose pulmonary irradiation in patients with covid-19 infection of bad prognosis

Conditions: COVID; Pneumonia, Viral

Summary: the administration of low-dose lung irradiation produces anti-inflammatory effects that will decrease the pulmonary inflammatory response. the present study will evaluate the efficacy of treatment with low-dose pulmonary radiotherapy added to standard support therapy, in hospitalized patients with respiratory symptoms due to covid-19 pneumonia, who do not experience improvement with conventional medical therapy and are not subsidiaries of icu

the who has officially confirmed that: "currently, there is no specific pharmacological available treatment for covid-19". beyond vital support, there are not currently treatment options for coronavirus disease (covid-19) and related pneumonia, the infection caused by severe acute respiratory syndrome coronavirus 2 (sars-cov-2). pulmonary irradiation is an option for the treatment of covid-19 pneumonia and could be available quickly and with a duration of about 15 minutes of treatment. thoracic irradiation therapy at very low doses (0.5-1.0 gy) dates back to the 1920s and was the only effective mean to treat certain infectious and inflammatory diseases prior to the development of antimicrobial therapies in the 1940s. the goal is to replicate low-dose radiation therapy, just as it was used 80 years ago for viral pneumonia with great success. it will be administered for a new disease, pneumonia caused by covid-19, for which there is no cure and many people are dying, mainly from severe acute respiratory syndrome leading to very severe hypoxemic acute respiratory failure refractory to treatment. this therapy is expected to remedy acute respiratory syndrome by reducing inflammation, and it also has a low risk of side effects and toxicities, given the low doses received, more than one hundred times lower, compared to the usual radiotherapy used to tumor treatment.

Eligibility criteria:
inclusion criteria: * patients over 65 years old * hospitalized with covid-19 positive not subsidiary of icu with severe disease defined by the presence of all the following characteristics: * presence of unilateral or bilateral pulmonary infiltrates in chest x-ray or computed tomography (ct). * acute respiratory failure expressed by pao2 / fio2 \<300. * lymphopenia ≤0.8 × 109 / l (800 lymphocytes / ml). * patients with ≤8 days from the onset of symptoms. exclusion criteria: * patient not consent to participate

Keywords: covid-19 pneumonia low dose radiotherapy
neurally adjusted ventilatory assist for weaning from invasive mechanical ventilation in critically ill children

Conditions: Mechanical Ventilator Weaning; Critically Ill; Mechanical Ventilation; Neurally Adjusted Ventilatory Assist

Summary: the goal of this clinical trial is to compare weaning from mechanical ventilation in critically ill children. the main questions it aims to answer are: * will weaning with neurally adjusted ventilatory assist (nava) mode ventilation result in shorter ventilator day than synchronised intermittent mandatory ventilation (simv) mode? * will weaning with nava mode ventilation result in shorter paediatric intensive care unit (picu) length of stay than simv mode? participants will be randomised to nava or simv group for weaning from mechanical ventilation, then picu outcomes from both groups will be collected, analysed and compared.


Eligibility criteria:
inclusion criteria: * all critically ill children admitted to picu exclusion criteria: * failure to obtain informed consent
hepatitis c infection in world trade center responders

Conditions: Hepatitis C Infection

Summary: this study provides hepatitis c virus screening to the members of the world trade center health program followed at the icahn school of medicine at mount sinai born during 1945-1965, and linkage to care for those found infected. the study will also determine if exposure to human remains, blood and/or bodily fluids during the world trade center health program activities are associated with hepatitis c virus infection. these findings would be relevant to the larger united states population, especially to persons born during 1945-1965 who are at high risk of hepatitis c virus infection.

the purpose of the project is to determine if the world trade center health program cohort is at an increased risk of hepatitis c virus infection, determine if human exposure to human remains, blood and/or body fluids during the world trade center recovery activities is associated with increased risk of hepatitis c virus infection, and to determine if referral to a co-located site for hepatitis c virus care is associated with improved linkage to hepatitis c virus care in the members of the world trade center health program born during 1945 through 1965.

Eligibility criteria:
inclusion criteria: * member of the world trade center health program at the icahn school of medicine at mount sinai * born during 1945-1965 exclusion criteria: * none

Keywords: hepatitis c virus linkage-to-care world trade center health program cohort baby boomer risk factors for hepatitis c virus infection
clinical outcomes of topical ganciclovir treatment in cytomegalovirus anterior uveitis

Conditions: Anterior Uveitis

Summary: the purpose of this study was to evaluate long term efficacy and safety of topical ganciclovir treatment in cytomegalovirus (cmv) anterior uveitis.

the investigators will enroll 60 patients with positive results of the cmv pcr (polymerase chain reaction) from aqueous humor tapping from january 2006 to june 2011. all the patients (40 men, 20 women) were immunocompetent and diagnosed as symptomatic cmv infection. their medical records will be reviewed, including demographic data as well as their ophthalmic and medical histories. the purpose of this study was to evaluate long term efficacy and safety of topical ganciclovir treatment in cmv anterior uveitis.

Eligibility criteria:
inclusion criteria: * patients with positive results of the cmv pcr (polymerase chain reaction) from aqueous humor tapping. all the patients were immunocompetent and diagnosed as symptomatic cmv infection. exclusion criteria: * patients without positive results of the cmv pcr * immunocompromised patients with positive results of the cmv pcr

Keywords: cytomegalovirus uveitis
split face study of the effects of micro needling with and without platelet rich plasma

Conditions: Aging

Summary: this pilot study will expand knowledge and application of 2 x concentration of platelet rich plasma (prp) in conjunction with microneedling using the skinpen device.

there have been numerous studies demonstrating benefits of microneedling. however, to date there is no published research expanding on the benefits of using platelet rich plasma in conjunction with microneedling for facial aesthetics. this pilot study will expand knowledge and application of 2 x concentration of platelet rich plasma (prp) in conjunction with microneedling using the skinpen device. the pilot aims to objectively measure skin quality using the visia systemtm and provide objective data to compare microneedling with the use of (prp) versus microneedling without the use of prp. the pilot also aims to subjectively measure skin improvement using the face qtm and the global aesthetic improvement scaletm.

Eligibility criteria:
inclusion criteria: * healthy males and females ages 30-60 years old. * no previous minimally invasive or invasive skin resurfacing within the prior 12 months (i.e. fractionated laser, ablated laser, chemical peels, microneedling, etc... * visiatm scan showing aging including skin texture, wrinkles, brown spots, and pores. * patient willing to sign informed consent. exclusion criteria: * keloid scars; * history of eczema in treatment area; psoriasis and any other chronic skin conditions the investigator determines disqualifies the patient for participation in treatment area; * history of actinic (solar) keratosis in treatment area; * history of hemophilia; * history of diabetes; * the presence of raised moles, warts on the targeted area. * absolute contraindications include; scleroderma, collagen vascular diseases or cardiac abnormalities; blood clotting problems; active bacterial or fungal infection; facial melanosis; malignant tumors, immunosuppression; use of blood thinners or prednisone; pregnant or nursing women; corticosteroids within two weeks of the procedure, chronic liver disease, porphyria or other skin diseases. * patient not willing to sign informed consent.
fimasartan blood pressure lowering after acute stroke

Conditions: Hypertension; Ischemic Stroke; Transient Ischemic Attack

Summary: this study evaluates the effectiveness of fimasartan-based antihypertensive treatment and prognosis in post-acute phase of ischemic stroke or transient ischemic attack patients. all participants will receive fimasartan, and the investigators will follow them up for 6 months.


Eligibility criteria:
inclusion criteria: * ischemic stroke or transient ischemic attack occurs after 7 days to 3 months. * mean blood pressure measured 3 times at the first visit (visit 1) should be over 140 mmhg for systolic blood pressure or 90 mmhg for diastolic blood pressure * suitable for administration of fimasartan * the life expectancy should be over 6 months. exclusion criteria: * patients already treated with antihypertensive medications * hemorrhagic stroke patients
study of viramidine to ribavirin in patients with chronic hepatitis c who are treatment naive

Conditions: Chronic Hepatitis C

Summary: the purpose of this study is to determine the safety and effectiveness of viramidine to ribavirin in chronic hepatitis c patients who have never before received treatment.

compare the efficacy and safety of viramidine 600 mg twice a day (bid) versus ribavirin 1000/1200 mg/day, both drugs administered in combination with pegylated interferon alfa-2a to treatment-naive patients with chronic hepatitis c (chc)

Eligibility criteria:
inclusion criteria: * treatment-naive patients with compensated chronic hepatitis c. * hcv rna \>2000 copies/ml (780 iu/ml) as determined by ngi superquant serum hcv rna quantification, with a lower limit of detection of 100 copies/ml (39 iu/ml). exclusion criteria: * severe neuropsychiatric disorders * history or clinical manifestations of significant metabolic, hematological, pulmonary, ischemic heart disease, significant or unstable heart disease, gastrointestinal, neurological, renal, urological, endocrine, ophthalmologic disorders including severe retinopathy, or immune mediated disease * pregnant or breast-feeding patients

Keywords: viramidine ribavirin valeant hepatitis c pegylated interferon alfa-2a
efficacy of pegetron® redipen™ treatment and treatment compliance of patients with chronic hepatitis c in canada (p04423)

Conditions: Hepatitis C, Chronic; Hepatitis C

Summary: treatment compliance is a key success factor in obtaining the full benefit of pegetron (peginterferon alfa-2b \[pegifn-2b\] plus ribavirin combination) therapy for patients. treatment-naïve patients with chronic hepatitis c (chc) in canada to whom pegetron redipen was prescribed will receive pegetron redipen therapy in accordance with approved labeling. the study will assess the effect of the newly approved pegetron redipen on treatment compliance and its effect on sustained virologic response rates. sustained virologic response is defined as negative hepatitis c virus ribonucleic acid (hcv-rna) six months post-treatment.


Eligibility criteria:
inclusion criteria: * treatment-naïve patients with chronic hepatitis c * adults (\>18 years of age) * prescribed pegetron redipen * must meet all requirements for treatment with pegetron redipen * must be able to obtain reimbursement of medication through private or provincial coverage exclusion criteria: * active hepatitis b virus (hbv) infection (hepatitis b surface antigen \[hbsag\] positive) * hiv antibody positive * post liver transplant patients * any other exclusion criteria as per the product monograph
characterisation of occupational allergy to drosophila

Conditions: Drosophila; Clinical Symptoms

Summary: allergy is a very common problem and can be a handicap in everyday life, specially when symptoms occur at work place. some persons working with drosophila developed respiratory symptoms. investigators tried to analyze if these manifestations could be due to a specific allergy to drosophila.

to do so, investigators invited laboratory workers who presented any symptoms in presence of drosophila to undergo skin prick tests in order to determine if a specific sensibilization to drosophila exists. then, a blood sample is taken from these persons to research specific ige directed against drosophila. by this way, investigators hope determine if a specific allergy to drosophila exists, its characteristics as prevalence, symptoms, populations concerned...in order to better protect laboratory workers and prevent allergy incidence.

Eligibility criteria:
inclusion criteria: * major males or females (aged \<68) who work in laboratory with drosophila in montpellier (france) * clinical symptoms in presence of drosophila * the subject must be affiliated to a social security scheme * provision of informed consent prior to any study specific procedures exclusion criteria: * the patient has indicated against (or incompatible drug combination) concerning the implementation of a prick test * antihistamine cure in progress * inability to understand the nature and goals of the study and / or communication difficulties with the investigator * no affiliation to a french social security recipient or not such a scheme * major protected by law (guardianship, curator or under judicial protection) * deprivation of liberty by judicial or administrative decision * increased likelihood of non compliance to the protocol or abandonment under study * pregnancy or breastfeeding
effect of statin therapy on c-reactive protein levels in patients with chronic obstructive lung disease (copd)

Conditions: COPD; Inflammation

Summary: hypothesis for this pilot study is that simvastatin will lower the levels of crp and et-1 in copd patients.

patients with chronic obstructive lung disease (copd) have an ongoing systemic inflammation, which can be assessed by measuring c-reactive protein (crp). crp is found to be a strong and independent predictor of future copd outcomes. statins are a class of cholesterol lowering drugs that decrease mortality from cardiovascular disease and stroke. in addition, they have anti-inflammatory, anti-thrombotic and immunomodulatory properties. statins lower c-reactive protein by the ability to reduce the production of interleukin (il)-6, the cytokine that activates the acute phase crp response. thus the rationale for this study is to evaluate effect of statins on the levels of crp and et-1 in copd patients.

Eligibility criteria:
inclusion criteria: * medically optimized copd patients * age 40-79 years. * serum crp levels \>3mg/l exclusion criteria: * current smoker * copd exacerbation in the last 2 months. * active hepatic or severe renal dysfunction. * connective tissue disease, chronic inflammatory disease, malignancy, any acute illness, leukocytosis (\>10,000 white blood cells) or thrombocytosis (\>450,000 platelets). * recent h/o myocardial infarction, angina in the last 6 months. * pregnancy.

Keywords: copd inflammation crp levels simvastatin
ultralow versus standard pneumoperitoneum pressure

Conditions: Prostate Cancer

Summary: the investigators plan to compare insufflation pressures during robotic assisted laparoscopic prostatectomy (ralp). standard pressure is typically 15 mmhg, while in a previous study the investigators determined that 6 mmhg is possible routinely. therefore, the investigators plan to compare the clinical outcomes of participants at a pneumoperitoneal pressure of 15 versus 6 mmhg.

the investigators to examine the impact of low pressure during robotic assisted laparoscopic prostatectomy (ralp) with the intention of identifying whether lower pressures might benefit participants. the investigators hypothesize that a low insufflation pressure may provide an improvement in postoperative pain and abdominal distension in addition to potential physiologic benefits, and that these factors might then allow a shorter hospital stay. the investigators previously initiated a protocol in september of 2016 (irb# 1066864) to perform ralps at an insufflation pressure of 6 mmhg with the intention of increasing the pressure as needed on an individual participant level. in order to determine whether this might allow earlier discharge when successful, the investigators began allowing for same-day discharge in participants meeting appropriate criteria. having now demonstrated feasibility in over 300 consecutive participants using this ultralow pneumoperitoneum protocol, the investigators now plan to conduct a randomized trial to compare a pressure of 6 mmhg with participants having ralp at a standard pressure of 15 mmhg to determine whether there is a true benefit.

Eligibility criteria:
inclusion criteria: 1. age 18 or older 2. diagnosed with prostate cancer 3. electing to undergo robotic assisted laparoscopic prostatectomy (ralp) exclusion criteria: 1. age \< 18 2. emergency surgery 3. patients with a significant preoperative dependence on narcotic medications 4. unable to give informed consent 5. dementia, history of dementia, or other significant mental impairment that would, in the opinion of the investigator, impede patient self-reporting 6. persons participating in any other research study involving an investigational drug or device or investigational surgical procedure that could interfere with the physiologic parameters being collected (for example, a study evaluating different anesthesia regimens that could confound study results) 7. non-english-speaking or reading

Keywords: prostatectomy robotic urology
effects of high intensity laser on mechanical and physiological findings in pregnant women with carpal tunnel syndrome

Conditions: Carpal Tunnel Syndrome; Pregnancy Related

Summary: this study will propose a novel approach to treat pregnant women with mild to moderate carpal tunnel syndrome (cts) using the recently introduced high intensity laser therapy with its deep penetration and high-power characteristics. it's hopeful that the results of this study can fill the gap of knowledge surrounding the conservative treatment options for cts in order to help patients restore their nerve function properly and promote new ways of addressing cts.


Eligibility criteria:
inclusion criteria: (1) pregnant women with mild to moderate cts diagnosed by a physician according to the american association of electrodiagnostic recent guidelines \[18\] (2) the age ranged between 20 to 40 years (3) had positive clinical provocative tests for the cts (tinel test and phalen test) and (5) had a history of pain, paresthesia or numbness in the median nerve distribution, nocturnal pain, and night waking exclusion criteria: patients were excluded from the study if they had cervical disc prolapse, cervical spondylosis, thoracic outlet syndrome, diabetes, gestational diabetes, cardiovascular disorders and hypertension. patients who had carpal tunnel release surgery and patients who were diagnosed with cts before pregnancy were also excluded from the study.

Keywords: carpal tunnel syndrome high intensity laser therapy electrophysiology pregnant women